2005 Compounding Drug Development 
European Pharmaceutical Review
JULY 13, 2023
3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.
European Pharmaceutical Review
JULY 4, 2024
4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2005 [cited 2024May]. 2012/1916). BMB Reports. 2017;50(3):111–6.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 8, 2022
To compound matters, the population demographic most at risk for lack of sleep are the older members of society who are also the most likely to have existing health problems. The advance of all of these digital health tools has led to the development of ‘novel digital endpoints’ (NDEs) to support drug development and regulatory applications.
Pharmaceutical Technology
JULY 23, 2008
It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.
Express Pharma
JULY 10, 2024
Over the past few years, several emerging trends such as pricing and inflation, technology implementation, focus on sustainability practices, the transition toward personalised and next-generation therapeutics, and innovative healthcare delivery models, are compounding the complexities within manufacturing and supply chain operations.
Expert insights. Personalized for you.
98 
Let's personalize your content